A Comprehensive Assessment to Predict Side Effects from Chemotherapy and an Evaluation of Pre-Phase Chemotherapy in Older Patients with Non-Hodgkin Lymphoma


Full Title

Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients with Non-Hodgkin Lymphoma with Imbedded Pilot Study of Pre-Phase Therapy


Older individuals are more likely to experience side effects from chemotherapy which may impair the effectiveness of treatment. Most people with non-Hodgkin lymphoma (NHL) are age 60 or older, putting them at increased risk of chemotherapy side effects. In this study, researchers want to learn which older patients are more likely to have side effects. Patients will complete a questionnaire and take a short walking test (measuring how quickly they get up from a chair and walk ten feet) before each cycle of chemotherapy. Researchers will compare the results of the questionnaire and walking test with each patient’s experience with side effects.

In a second part of the study, patients with a type of NHL called diffuse large B-cell lymphoma (DLBCL) may receive two drugs before their chemotherapy — prednisone and rituximab — which may help lower the side effects of chemotherapy. These patients will then answer the questionnaire and take the same walking test before receiving chemotherapy.

The following video explains the basic principles and goals of the study for all participants.


The following video explains the basic principles and goals of the study, as well as the second part of the study where some patients with diffuse large B-cell lymphoma receive prednisone and rituximab before chemotherapy to try to lower the incidence of treatment side effects.



To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must be age 60 or older and have NHL. Patients in the DLBCL part of the study must be age 70 or older.
  • Patients must be starting a new treatment regimen for NHL.
  • Patients must be fluent in English so they can answer the questions that are part of the assessment.

For more information about this study and to inquire about eligibility, please contact Dr. Paul A. Hamlin at 212-639-6143.







Zelenetz, Andrew, MD, PhD